186 related articles for article (PubMed ID: 16904220)
1. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.
Saul JM; Annapragada AV; Bellamkonda RV
J Control Release; 2006 Sep; 114(3):277-87. PubMed ID: 16904220
[TBL] [Abstract][Full Text] [Related]
2. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
4. In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells.
Asadishad B; Vossoughi M; Alamzadeh I
Biotechnol Lett; 2010 May; 32(5):649-54. PubMed ID: 20131082
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
Gabizon A; Shmeeda H; Horowitz AT; Zalipsky S
Adv Drug Deliv Rev; 2004 Apr; 56(8):1177-92. PubMed ID: 15094214
[TBL] [Abstract][Full Text] [Related]
6. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo.
Song S; Liu D; Peng J; Sun Y; Li Z; Gu JR; Xu Y
Int J Pharm; 2008 Nov; 363(1-2):155-61. PubMed ID: 18692120
[TBL] [Abstract][Full Text] [Related]
7. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
8. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
9. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
Kawano K; Onose E; Hattori Y; Maitani Y
Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
[TBL] [Abstract][Full Text] [Related]
10. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.
Acharya S; Dilnawaz F; Sahoo SK
Biomaterials; 2009 Oct; 30(29):5737-50. PubMed ID: 19631377
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
12. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
13. Folate targeting of drug carriers: a mathematical model.
Ghaghada KB; Saul J; Natarajan JV; Bellamkonda RV; Annapragada AV
J Control Release; 2005 May; 104(1):113-28. PubMed ID: 15866339
[TBL] [Abstract][Full Text] [Related]
14. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
Kukowska-Latallo JF; Candido KA; Cao Z; Nigavekar SS; Majoros IJ; Thomas TP; Balogh LP; Khan MK; Baker JR
Cancer Res; 2005 Jun; 65(12):5317-24. PubMed ID: 15958579
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor.
Taniguchi Y; Kawano K; Minowa T; Sugino T; Shimojo Y; Maitani Y
Cancer Sci; 2010 Oct; 101(10):2207-13. PubMed ID: 20608940
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
18. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier.
Huang SJ; Sun SL; Feng TH; Sung KH; Lui WL; Wang LF
Eur J Pharm Sci; 2009 Aug; 38(1):64-73. PubMed ID: 19540339
[TBL] [Abstract][Full Text] [Related]
19. Tumour-selective drug delivery via folate receptor-targeted liposomes.
Pan X; Lee RJ
Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
Carrion C; de Madariaga MA; Domingo JC
Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
